Urologix Doubles Presence In BPH Treatment Via $20 Mil. Prostatron Buy
This article was originally published in The Gray Sheet
Executive Summary
Addition of Edap's Prostatron transurethral microwave thermotherapy (TUMT) system for treatment of benign prostatic hyperplasia (BPH) doubles Urologix' market presence in the BPH treatment area, the firm says. Urologix also expects the total number of cooled microwave thermotherapy procedures performed "to double in the next year" due to expanded market acceptance of the treatment.
You may also be interested in...
Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed
Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043
Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed
Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043
Urologix Targis TUMT Production To Resume By Year-End
Urologix expects to resume production of its Targis transurethral microwave thermotherapy (TUMT) system for benign prostatic hyperplasia by year-end after manufacturing partner Colorado MEDtech corrects several quality system deficiencies.